Pharmafile Logo
Pharmafocus logo
Advanced Search

leukaemia

Showing 15 posts of 91 posts found.

Qlucore and Sahlgrenska Hospital sign agreement for ALL diagnosis software

January 17, 2024
Business Services Oncology, Qlucore, Sahlgrenska Hospital, acute lymphoblastic leukaemia, leukaemia

Qlucore has announced that it has entered into an agreement with Sahlgrenska Hospital, in Gothenberg, Sweden. This agreement means the …

News

Eli Lilly’s Jaypirca approved in US for leukaemia and lymphoma treatment

December 4, 2023
Medical Communications Eli Lilly, FDA, Jaypirca, Oncology, leukaemia, lymphoma

Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Jaypirca (pirtobrutinib, 100mg and 50mg tablets) …

News
acute_lymphoblastic_leukaemia_smear

Astellas Pharma and BMT CTN announce phase 3 data for gilteritinib

June 9, 2023
Research and Development Astellas Pharma, BMT CTN, Haematology, gilteritinib, leukaemia, pharmaceutical

Japanese pharmaceutical company Astellas Pharma and the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) have presented their phase …

News
astrazeneca_sign_sky

NICE recommendation for AstraZeneca’s Calquence in chronic lymphocytic leukaemia populations

December 8, 2020
Manufacturing and Production, Sales and Marketing AstraZeneca, NHS, NICE, UK, leukaemia

The National Institute for Health and Care Excellence (NICE) has recommended that AstraZeneca’s Calquence (acalabrutinib) be used on the NHS in …

News
nice_reception_2

NICE recommends venetoclax combo, a non-chemo option for untreated chronic lymphocytic leukaemia

November 10, 2020
Manufacturing and Production, Sales and Marketing AbbVie, NHS, NICE, UK, leukaemia, venetoclax

NICE has recommended venetoclax in combination with obinutuzumab under final draft guidance for the first-line treatment of untreated chronic lymphocytic …

News
mr_robot_cancer

AbbVie’s Venclexta plus azacitidine shows improved survival and remissions rates in leukaemia patients

June 15, 2020
Sales and Marketing AbbVie, leukaemia

AbbVie have announced positive results from its latest Phase 3 clinical trial where Venclexta plus azacitidine improved survival and remission …

News
gilead-sciences

Gilead’s magrolimab shows promising responses in untreated myelodysplastic syndrome and acute myeloid leukaemia at ASCO 2020

June 1, 2020
Research and Development, Sales and Marketing ASCO 2020, Cancer, Gilead, leukaemia, magrolimab

Gilead took the opportunity at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting to unveil new Phase 1b …

News
trialy

Leukaemia drug nilotinib shows promise against Alzheimer’s in small clinical study

May 29, 2020
Medical Communications Alzheimer's, leukaemia

The leukemia drug nilotinib has shown promise in reducing the effects of Alzheimer’s disease and while having safe and minimal …

News
abbvie_0

AbbVie’s Imbruvica scoops up 11th FDA approval with chronic lymphocytic leukaemia/small lymphocytic lymphoma nod

April 22, 2020
Research and Development, Sales and Marketing Cancer, FDA, imbruvica, leukaemia

AbbVie’s Imbruvica (ibrutinib) has scored its 11th FDA approval, this time in combination with rituximab for the treatment of chronic …

News
000000000000000_tttt

Researchers modify T-cells to identify and target multiple sites on leukaemia cells

April 1, 2020
Research and Development Cancer, Cancers, children cancer, leukaemia

Scientists from the Children’s Hospital of Los Angeles have engineered T-cells to identify and target multiple sites on acute lymphoblastic …

News

AstraZeneca’s trial of leukaemia drug Calquence yields positive results

December 9, 2019
Sales and Marketing AstraZeneca, Calquence, leukaemia, phase 3

AstraZeneca confirmed it had recorded positive results from its Phase 3 trial of Calquence plus obinutuzumab in leukaemia. The trial …

News

Sanofi acquires biotech firm Synthorx for $2.5 billion

December 9, 2019
Sales and Marketing Genetic Alphabet, Sanofi, acute lymphoblastic leukaemia, leukaemia

Sanofi has agreed to buy California-based biotechnology firm Synthrox, in a deal worth about $2.5 billion (£1.95 billion). Paul Hudson, …

News

FDA approves AstraZeneca’s Calquence in chronic lymphoma

November 25, 2019
Sales and Marketing Astrazenaca, Calquence, FDA, Health Canada, leukaemia, oncology

The FDA has approved AstraZeneca’s BTK inhibitor Calquence (acalabrutinib) in the treatment of chronic lymphocytic leukaemia (CLL) and small lymphocytic …

News

European approval announced for Astellas’ Xospata in FLT3+ treatment-resistant acute myeloid leukaemia

October 28, 2019
Sales and Marketing Astellas, Xospata, leukaemia, pharma

Astellas has revealed that the European Commission has awarded marketing approval for Xospata (gilteritinib) as an oral, once-daily monotherapy for …

News
janssen_latest_logo_on_sign

Janssen’s Imbruvica shows superiority in Phase 3 trials

June 4, 2019
Manufacturing and Production Janssen, imbruvia, leukaemia, pharma, phase 3, trial

Phase 3 data from ASCO 2019 has shown Janssen’s leukaemia drug Imbruvica (ibrutinib) had significant benefits over ofatumumab. In the …

News

Latest content

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024